S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

$16.53
+0.58 (+3.64%)
(As of 03/27/2024 ET)
Today's Range
$16.23
$17.01
50-Day Range
$11.62
$16.53
52-Week Range
$8.08
$41.45
Volume
476,790 shs
Average Volume
278,271 shs
Market Capitalization
$349.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33

Enanta Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
17.0% Upside
$19.33 Price Target
Short Interest
Bearish
12.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.80mentions of Enanta Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.90) to ($4.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

296th out of 939 stocks

Pharmaceutical Preparations Industry

133rd out of 422 stocks

ENTA stock logo

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Stock Price History

ENTA Stock News Headlines

Enanta Pharmaceuticals Inc
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
ENTA Enanta Pharmaceuticals, Inc.
ENTA Oct 2024 20.000 call
ENTA Oct 2024 22.500 call
ENTA Oct 2024 10.000 put
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Q1 2024 Enanta Pharmaceuticals Inc Earnings Call
Recap: Enanta Pharma Q1 Earnings
Earnings Preview For Enanta Pharma
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/27/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ENTA
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.33
High Stock Price Target
$28.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+17.0%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-133,820,000.00
Net Margins
-187.77%
Pretax Margin
-184.73%

Debt

Sales & Book Value

Annual Sales
$79.20 million
Book Value
$10.29 per share

Miscellaneous

Free Float
18,270,000
Market Cap
$349.77 million
Optionable
Optionable
Beta
0.44
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Jay R. Luly Ph.D. (Age 68)
    President, CEO & Director
    Comp: $1.25M
  • Mr. Paul J. Mellett Jr.Mr. Paul J. Mellett Jr. (Age 69)
    Senior VP of Finance & Administration and CFO
    Comp: $666.84k
  • Dr. Yat Sun Or Ph.D. (Age 72)
    Senior VP of Research & Development and Chief Scientific Officer
    Comp: $729.31k
  • Mr. Nathaniel S. Gardiner J.D. (Age 70)
    Senior VP, General Counsel & Secretary
    Comp: $672.67k
  • Mr. Brendan Luu (Age 49)
    Senior Vice President of Business Development
    Comp: $622.86k
  • Ms. Jennifer Viera
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Tara Lynn Kieffer Ph.D. (Age 46)
    Senior Vice President of New Product Strategy & Development
    Comp: $496.85k
  • Dr. Scott T. Rottinghaus M.D. (Age 50)
    Senior VP & Chief Medical Officer
    Comp: $616.73k

ENTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price target for 2024?

6 Wall Street research analysts have issued 12-month price objectives for Enanta Pharmaceuticals' stock. Their ENTA share price targets range from $11.00 to $28.00. On average, they predict the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 17.0% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2024?

Enanta Pharmaceuticals' stock was trading at $9.41 at the start of the year. Since then, ENTA shares have increased by 75.7% and is now trading at $16.53.
View the best growth stocks for 2024 here
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,410,000 shares, an increase of 15.3% from the February 29th total of 2,090,000 shares. Based on an average daily volume of 263,300 shares, the short-interest ratio is presently 9.2 days. Approximately 12.3% of the shares of the company are sold short.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by $0.40. The biotechnology company earned $18 million during the quarter, compared to analysts' expectations of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative trailing twelve-month return on equity of 60.38%.

What ETF holds Enanta Pharmaceuticals' stock?

Amplify Treatments, Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.75%), Vanguard Group Inc. (8.48%), Vanguard Group Inc. (8.48%), Northern Trust Corp (4.42%), Assenagon Asset Management S.A. (2.77%) and Goldman Sachs Group Inc. (0.88%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENTA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners